Association of IL-10, IL-4, and IL-28B gene polymorphisms with spontaneous clearance of hepatitis C virus in a population from Rio de Janeiro

BMC Research Notes

Edson Rondinelli⁵  Lia Lewis-Ximenez³  Cristiane Alves Villella-Nogueira⁴  Turán Péter Ürményi¹  Pedro Hernan Cabello³  Ana Lucia Araújo Ramos⁴  Luísa Hoffmann¹  Rosane Silva⁵  Juliene Antonio Ramos² 

[1] Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil;Instituto Federal de Educação Ciência e Tecnologia do Rio de Janeiro, Rio de Janeiro, Brazil;Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil;Departamento de Clínica Médica, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil;Instituto Nacional para Pesquisa Translacional em Saúde e Ambiente na Região Amazônica, Conselho Nacional de Desenvolvimento Científico e Tecnológico/MCT, Rio de Janeiro, Brazil

关键词: Gene polymorphism;    Cytokines;    Spontaneous viral clearance;    HCV;    Chronic hepatitis C;    Acute hepatitis C;   

Others  :  1165664
DOI  :  10.1186/1756-0500-5-508

 received in 2012-03-12, accepted in 2012-09-12,  发布年份 2012

【 摘 要 】

Background

Cytokines play an important role in the regulation of the immune response. In hepatitis C virus (HCV) infection, cytokine levels may influence the outcome of acute HCV infection. Polymorphisms in cytokine genes have been associated to different expression levels in response to infection. This study was carried out to investigate the association of several cytokine gene polymorphisms with disease outcome in HCV-infected patients.

Findings

Patients with chronic or spontaneously resolved HCV infection were included in a cross-sectional study. A comparative analysis was performed between the groups regarding frequency distribution of the following cytokines’ gene polymorphisms: IL-10 (−1082 A/G; -819 T/C; -592 A/C), IL-4 (+33C/T), IFN-γ (+874 T/A), TNF-α (−238 G/A and −308 G/A) and IL-28B (rs12979860 C/T and rs8099917 T/G). Results: Eighteen patients with spontaneous viral clearance and 161 with chronic HCV infection were included. In the comparative analysis, the GG genotype of the IL-10 polymorphism -1082A/G was more frequent in patients with spontaneous viral clearance when compared to patients with chronic HCV (41.2% vs 6.2%; p = 0.001). This association was also found for the CC genotype of the IL-4 polymorphism +33C/T (72.2% vs 36.7%; p = 0.017) and the CC and TT genotypes of the IL-28B polymorphisms rs 12979860 and rs 8099917 (88.9% vs 30.3%; p < 0.001 and 88.9% vs 49.6%; p = 0.002). The IL10 (A-1082 G) and IL-28B (Crs12979860T) gene polymorphisms showed odds ratios of 12.848 and 11.077, respectively, and thus may have a greater influence on HCV spontaneous viral clearance. The IFN-γ (+874 T/A), TNF-α (−238 G/A and −308 G/A) polymorphisms did not show significant association with spontaneous viral clearance or chronicity.

Conclusion

The G allele for IL-10 (−1082 A/G), the C allele for IL-4 (+3 C/T) and the C and T alleles for IL-28B (rs12979860 and rs8099917, respectively) are associated with spontaneous viral clearance in hepatitis C infection.

【 授权许可】

   
2012 Ramos et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Seeff LB: Natural history of chronic hepatitis C. Hepatology 2002, 36(suppl 1):S35-S46.
• [2]Barrett S, Ryan E, Crowe J: Association of the HLA-DRB1*01 allele with spontaneous viral clearance in an Irish cohort infected with hepatitis C virus via contaminated anti-D immunoglobulin. J Hepatol 1999, 30:979-983.
• [3]Hohler T, Kruger A, Gerken G, Schneider PM, Meyer zum Buschenfelde KH, Rittner C: Tumor necrosis factor alpha promoter polymorphism at position −238 is associated with chronic active hepatitis C infection. J Med Virol 1998, 54:173-177.
• [4]Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, Shorthouse C, Purdie DM, Jonsson JR: Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000, 31:828-833.
• [5]Tsutsumi T, Suzuki T, Shimoike T, Suzuki R, Moriya K, Shintani Y, Fujie H, Matsuura Y, Koike K, Miyamura T: Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity. Hepatology 2002, 35:937-946.
• [6]Cacciarelli TV, Martinez OM, Gish RG, Villanueva JC, Krams SM: Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. Hepatology 1996, 24:6-9.
• [7]Quiroga JA, Martin J, Pardo M, Carreno V: Serum levels of soluble immune factors and pathogenesis of chronic hepatitis C, and their relation to therapeutic response to interferon-alpha. Dig Dis Sci 1994, 39:2485-2496.
• [8]Luomala M, Lehtimaki T, Huhtala H, Ukkonen M, Koivula T, Hurme M, Elovaara I: Promoter polymorphism of IL-10 and severity of multiple sclerosis. Acta Neurol Scand 2003, 108:396-400.
• [9]Shin HD, Winkler C, Stephens JC, Bream J, Young H, Goedert JJ, O’Brien TR, Vlahov D, Buchbinder S, Giorgi J, et al.: Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci USA 2000, 97:14467-14472.
• [10]Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB: Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 2004, 22:929-979.
• [11]Pravica V, Asderakis A, Perrey C, Hajeer A, Sinnott PJ, Hutchinson IV: In vitro production of IFN-gamma correlates with CA repeat polymorphism in the human IFN-gamma gene. Eur J Immunogenet 1999, 26:1-3.
• [12]Nelson DR, Lauwers GY, Lau JY, Davis GL: Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 2000, 118:655-660.
• [13]Lio D, Caruso C, Di Stefano R, Colonna Romano G, Ferraro D, Scola L, Crivello A, Licata A, Valenza LM, Candore G, et al.: IL-10 and TNF-alpha polymorphisms and the recovery from HCV infection. Hum Immunol 2003, 64:674-680.
• [14]Gajewski TF, Joyce J, Fitch FW: Antiproliferative effect of IFN-gamma in immune regulation. III. Differential selection of TH1 and TH2 murine helper T lymphocyte clones using recombinant IL-2 and recombinant IFN-gamma. J Immunol 1989, 143:15-22.
• [15]di Iulio J, Ciuffi A, Fitzmaurice K, Kelleher D, Rotger M, Fellay J, Martinez R, Pulit S, Furrer H, Günthard HF, et al.: Estimating the net contribution of interleukin-28B variant to spontaneous hepatitis C virus clearance. Hepatology 2011, 531:1446-1454.
• [16]Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, et al.: Genome-wide association of IL-28B with response to pegylated interferon-α and ribavirina therapy for chronic hepatitis C. Nat Genet 2009, 1-5.
• [17]Hershey GK: IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol 2003, 111:677-690.
• [18]Napoli J, Bishop GA, McGuinness PH, Painter DM, McCaughan GW: Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 1996, 24:759-765.
• [19]Dharancy S, Podevin P, Aoudjehane L, Batteux F, Rosenberg AR, Soubrane O, Calmus Y, Conti F: Elevated interleukin-4 expression in severe recurrent hepatitis C virus after liver transplantation. Transplantation 2007, 83:906-911.
• [20]Chen TY, Hsieh YS, Wu TT, Yang SF, Wu CJ, Tsay GJ, Chiou HL: Impact of serum levels and gene polymorphism of cytokines on chronic hepatitis C infection. Transl Res 2007, 150:116-121.
• [21]Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV: An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997, 24:1-8.
• [22]Pereira FA, da Silva NN P, Rodart IF, Carmo TM, Lemaire DC, Reis MG: Association of TGF-beta1 codon 25 (G915C) polymorphism with hepatitis C virus infection. J Med Virol 2008, 80:58-64.
• [23]Ben-Ari Z, Pappo O, Druzd T, Sulkes J, Klein T, Samra Z, Gadba R, Tambur AR, Tur-Kaspa R, Mor E: Role of cytokine gene polymorphism and hepatic transforming growth factor beta1 expression in recurrent hepatitis C after liver transplantation. Cytokine 2004, 27:7-14.
• [24]Nelson DR, Lim HL, Marousis CG, Fang JW, Davis GL, Shen L, Urdea MS, Kolberg JA, Lau JY: Tivation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig Dis Sci 1997, 42:2487.
• [25]Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, et al.: IL-28B is association with response to chronic hepatitis C interferon-alpha and ribavirina therapy. Nat Genet 2009, 10:1100-1104.
• [26]Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, et al.: Genetic variation in IL-28B predicts hepatitis C treatment induced viral clearance. Nature 2009, 461:399-401.
• [27]Tanaka Y, Nishida N, Sugiyama M, Tokunaga K, Mizokami M: lambda-Interferons and the single nucleotide polymorphisms: a milestone to tailor-made therapy for chronic hepatitis C. Hepatol Res 2010, 40:449-460.
• [28]Mangia A: IL28B: a new wager in the skyline of hepatitis C virus infection. Dig Liver Dis 2010, 43:177-179.
• [29]Doehring A, Hofmann WP, Schlecker C, Zeuzem S, Susser S, Geisslinger G, Sarrazin C, Lotsch J: Screening for IL28B gene variants identifies predictors of hepatitis C therapy success. Antivir Ther 2010, 15:1099-1106.
• [30]Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, et al.: Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterolgy 2010, 138:1338-1345.
• [31]Lewis-Ximenez LL, Lauer GM, Schulze Zur Wiesch J, De Sousa PS, Ginuino CF, Paranhos-Baccalá G, Ulmer H, Pfeiffer KP, Goebel G, Pereira JL, Oliveira de Mendes J, et al.: Prospective follow-up of patients with acute hepatitis C virus infection in Brazil. Clin Infect Dis 2010, 50:1222-1230.
• [32]Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1998, 16:1215.